Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity
Liu, Xin-Wei3; Yang, Jun-Ling3; Niu, Wei3; Jia, Wei-Wei3; Olaleye, Olajide E3; Wen, Qi3; Duan, Xiao-Na3; Huang, Yü-Hong1; Wang, Feng-Qing3; Du, Fei-Fei3
刊名Acta pharmacologica Sinica
2018-12
卷号39期号:12页码:1935-1946
ISSN号1745-7254
DOI10.1038/s41401-018-0086-7
文献子类Article
英文摘要Terpene lactones are a class of bioactive constituents of standardized preparations of Ginkgo biloba leaf extract, extensively used as add-on therapies in patients with ischemic cardiovascular and cerebrovascular diseases. This investigation evaluated human pharmacokinetics of ginkgo terpene lactones and impact of their carboxylation in blood. Human subjects received oral YinXing-TongZhi tablet or intravenous ShuXueNing, two standardized ginkgo preparations. Their plasma protein-binding and platelet-activating factor antagonistic activity were assessed in vitro. Their carboxylation was assessed in phosphate-buffered saline (pH 7.4) and in human plasma. After dosing YinXing-TongZhi tablet, ginkgolides A and B and bilobalide exhibited significantly higher systemic exposure levels than ginkgolides C and J; after dosing ShuXueNing, ginkgolides A, B, C, and J exhibited high exposure levels. The compounds' unbound fractions in plasma were 45-92%. Apparent oral bioavailability of ginkgolides A and B was mostly >100%, while that of ginkgolides C and J was 6-15%. Bilobalide's bioavailability was probably high but lower than that of ginkgolides A/B. Terminal half-lives of ginkgolides A, B, and C (4-7 h) after dosing ShuXueNing were shorter than their respective values (6-13 h) after dosing YinXing-TongZhi tablet. Half-life of bilobalide after dosing the tablet was around 5 h. Terpene lactones were roughly evenly distributed in various body fluids and tissues; glomerular-filtration-based renal excretion was the predominant elimination route for the ginkgolides and a major route for bilobalide. Terpene lactones circulated as trilactones and monocarboxylates. Carboxylation reduced platelet-activating factor antagonistic activity of ginkgolides A, B, and C. Ginkgolide J, bilobalide, and ginkgo flavonoids exhibited no such bioactivity. Collectively, differences in terpene lactones' exposure between the two preparations and influence of their carboxylation in blood should be considered in investigating the relative contributions of terpene lactones to ginkgo preparations' therapeutic effects. The results here will inform rational clinical use of ginkgo preparations.
语种英语
内容类型期刊论文
源URL[http://119.78.100.183/handle/2S10ELR8/266658]  
专题上海药物代谢研究中心
科研与新药推进处
通讯作者Li, Li; Li, Chuan
作者单位1.Second Affiliated Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin, 300250, China;
2.SPH XingLing Science & Technology Pharmaceutical Co., Ltd., Shanghai, 201703, China
3.State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China;
推荐引用方式
GB/T 7714
Liu, Xin-Wei,Yang, Jun-Ling,Niu, Wei,et al. Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity[J]. Acta pharmacologica Sinica,2018,39(12):1935-1946.
APA Liu, Xin-Wei.,Yang, Jun-Ling.,Niu, Wei.,Jia, Wei-Wei.,Olaleye, Olajide E.,...&Li, Chuan.(2018).Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity.Acta pharmacologica Sinica,39(12),1935-1946.
MLA Liu, Xin-Wei,et al."Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity".Acta pharmacologica Sinica 39.12(2018):1935-1946.
个性服务
查看访问统计
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。


©版权所有 ©2017 CSpace - Powered by CSpace